allogeneic anti-CD33 CAR T cells VCAR33

A preparation of allogeneic T lymphocytes, derived from the same matched healthy donor who provided a stem cell transplant and transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) specific for the CD33 antigen, with potential immunomodulating and antineoplastic activities. Upon administration, allogeneic anti-CD33 CAR T cells VCAR33 specifically recognize and kill CD33-expressing tumor cells. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and is overexpressed on myeloid leukemia cells.